Portal de Periódicos da CAPES

IL-10-Engineered Human CD4+ Tr1 Cells Eliminate Myeloid Leukemia in an HLA Class I-Dependent Mechanism

2024; Elsevier BV; Volume: 32; Issue: 3 Linguagem: Inglês

10.1016/j.ymthe.2024.02.012

1525-0024

Grazia Locafaro, Grazia Andolfi, Fabio Russo, Luca Cesana, Antonello E. Spinelli, Barbara Camisa, Fabio Ciceri, Angelo Lombardo, Attilio Bondanza, Maria Grazia Roncarolo, Silvia Gregori,

CAR-T cell therapy research

(Molecular Therapy 25, 2254–2269; October 2017) In the originally published version of this article, there is an error in Figure 8A, where there is a duplication of the mouse pictures at day 5 and day 7. The error occurred during the editing of Figure 8A and does not affect the overall conclusion of the paper. A corrected version of the figure is provided below. The authors apologize for this error and any confusion this may have caused. IL-10-Engineered Human CD4+ Tr1 Cells Eliminate Myeloid Leukemia in an HLA Class I-Dependent MechanismLocafaro et al.Molecular TherapyJuly 4, 2017In BriefTr1 cells are generated by overexpressing IL-10 in CD4+ T cells (CD4IL-10). In this issue of Molecular Therapy, Locafaro et al. (2017) show that CD4IL-10 cells kill myeloid leukemia in an HLA class I-dependent mechanism, mediate anti-tumor and anti-leukemic effects, and contribute to GvL while preventing GvHD in humanized mice. Full-Text PDF Open Access